S-H Liu1, C E Dubé2, J B Driban3, T E McAlindon4, C B Eaton5, K L Lapane6. 1. Clinical and Population Health Research Program, Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA, 01655, USA. Electronic address: ShaoHsien.Liu@umassmed.edu. 2. Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, 01605, USA. Electronic address: Catherine.Dube@umassmed.edu. 3. Division of Rheumatology, Tufts Medical Center, Boston, MA, 02111, USA. Electronic address: Jeffrey.Driban@tufts.edu. 4. Division of Rheumatology, Tufts Medical Center, Boston, MA, 02111, USA. Electronic address: tmcalindon@tuftsmedicalcenter.org. 5. Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, RI, 02860, USA; Departments of Family Medicine and Epidemiology, Warren Alpert Medical School, School of Public Health, Brown University, Providence, RI, 02912, USA. Electronic address: Charles_Eaton@mhri.org. 6. Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, 01605, USA. Electronic address: Kate.Lapane@umassmed.edu.
Abstract
OBJECTIVE: We sought to describe and evaluate longitudinal use of intra-articular injections after treatment initiation among adults with radiographically confirmed knee osteoarthritis (OA). METHOD: Using data from the Osteoarthritis Initiative (OAI), we included participants with radiographically confirmed OA (Kellgren-Lawrence grade (K-L) ≥ 2) in ≥1 knee at baseline. With 9 years of data, 412 participants newly initiating hyaluronic acid or corticosteroid injections with their index visit were identified. For each type of injection initiated, socio-demographic and clinical characteristics were described by patterns of treatments (one-time use, switched, or continued injections). Multinomial logistic models estimated the extent to which patient-reported symptoms (post-initial injection and changes over time) were associated with patterns of injection use. RESULTS: Of those initiating injections, ∼19% switched, ∼21% continued injection type, and ∼60% did not report any additional injections. For participants initiating corticosteroid injections, greater symptoms post-initial injection were associated with lower odds of continued use compared to one-time users (adjusted odds ratio (aOR) for Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain: 0.91; 95%, confidence interval (CI): 0.83 to 0.99; aORstiffness: 0.77; CI: 0.63 to 0.94; aORphysical function: 0.97; CI: 0.94 to 1.00). Symptom changes over time (e.g., worsened or improved) were not associated with patterns of injections use. CONCLUSION: After treatment initiation, the proportion of patients switching injection use and one-time users was substantial. Symptoms post-initial injection appear to be associated with patterns of injection use. The extent to which these patterns are an indication of lack of impact on patient-reported symptoms should be explored.
OBJECTIVE: We sought to describe and evaluate longitudinal use of intra-articular injections after treatment initiation among adults with radiographically confirmed knee osteoarthritis (OA). METHOD: Using data from the Osteoarthritis Initiative (OAI), we included participants with radiographically confirmed OA (Kellgren-Lawrence grade (K-L) ≥ 2) in ≥1 knee at baseline. With 9 years of data, 412 participants newly initiating hyaluronic acid or corticosteroid injections with their index visit were identified. For each type of injection initiated, socio-demographic and clinical characteristics were described by patterns of treatments (one-time use, switched, or continued injections). Multinomial logistic models estimated the extent to which patient-reported symptoms (post-initial injection and changes over time) were associated with patterns of injection use. RESULTS: Of those initiating injections, ∼19% switched, ∼21% continued injection type, and ∼60% did not report any additional injections. For participants initiating corticosteroid injections, greater symptoms post-initial injection were associated with lower odds of continued use compared to one-time users (adjusted odds ratio (aOR) for Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain: 0.91; 95%, confidence interval (CI): 0.83 to 0.99; aORstiffness: 0.77; CI: 0.63 to 0.94; aORphysical function: 0.97; CI: 0.94 to 1.00). Symptom changes over time (e.g., worsened or improved) were not associated with patterns of injections use. CONCLUSION: After treatment initiation, the proportion of patients switching injection use and one-time users was substantial. Symptoms post-initial injection appear to be associated with patterns of injection use. The extent to which these patterns are an indication of lack of impact on patient-reported symptoms should be explored.
Authors: B M Psaty; T D Koepsell; D Lin; N S Weiss; D S Siscovick; F R Rosendaal; M Pahor; C D Furberg Journal: J Am Geriatr Soc Date: 1999-06 Impact factor: 5.562
Authors: Aman Dhawan; Richard C Mather; Vasili Karas; Michael B Ellman; Benjamin B Young; Bernard R Bach; Brian J Cole Journal: Arthroscopy Date: 2013-11-28 Impact factor: 4.772
Authors: M Langman; K H Kahler; S X Kong; Q Zhang; E Finch; J D Bentkover; E J Stewart Journal: Pharmacoepidemiol Drug Saf Date: 2001 Oct-Nov Impact factor: 2.890
Authors: Kate L Lapane; Shao-Hsien Liu; Catherine E Dubé; Jeffrey B Driban; Timothy E McAlindon; Charles B Eaton Journal: Clin Ther Date: 2017-01-28 Impact factor: 3.393
Authors: Vikki Wylde; Andrew J Moore; Edith Anderson; Richard Donovan; Ashley W Blom; Andrew Judge; Michael R Whitehouse Journal: Osteoarthr Cartil Open Date: 2022-09
Authors: Shao-Hsien Liu; Catherine E Dubé; Charles B Eaton; Jeffrey B Driban; Timothy E McAlindon; Kate L Lapane Journal: J Rheumatol Date: 2018-06-15 Impact factor: 4.666
Authors: Shao-Hsien Liu; Stavroula A Chrysanthopoulou; Qiuzhi Chang; Jacob N Hunnicutt; Kate L Lapane Journal: Med Care Date: 2019-03 Impact factor: 3.178